GIP receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-07. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
The two substrates of this enzyme are (S,S)-butane-2,3-diol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are (S)-acetoin, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (S,S)-butane-2,3-diol:NAD+ oxidoreductase. Other names in common use include L-butanediol dehydrogenase, L-BDH, and L(+)-2,3-butanediol dehydrogenase (L-acetoin forming). This enzyme participates in butanoic acid metabolism.
He was succeeded by Robin Dutt, who himself left the club for Bayer Leverkusen in 2011. On 10 May 2009, Freiburg secured promotion into the Bundesliga once again, beating TuS Koblenz in an away game 5–2.
=== Nationwide === 99 Speedmart AEON Group AEON AEON MaxValu Prime AEON BiG (Formerly Carrefour) DAISO AgroBazaar Econsave Giant Hypermarket KK Mart Lotus's (Formerly Tesco, Tesco Extra) Mydin Eco-Shop MR.DIY
On 5 October 1959, Trieste departed San Diego for Guam aboard the freighter Santa Maria to participate in Project Nekton, a series of very deep dives in the Mariana Trench. On 23 January 1960, Trieste reached the ocean floor in the Challenger Deep (the deepest southern part of the Mariana Trench), carrying Jacques Piccard (son of Auguste) and Lieutenant Don Walsh, USN. This was the first time a vessel, crewed or uncrewed, had reached the deepest point in the Earth's oceans. The onboard systems indicated a depth of 11,521 metres (37,799 ft), although this was later revised to 10,916 metres (35,814 ft) and more accurate measurements made in 1995 have found the Challenger Deep slightly shallower, at 10,911 metres (35,797 ft). Building a pressure hull is difficult, as it must withstand pressures at its required diving depth. When the hull is perfectly round in cross-section, the pressure is evenly distributed, and causes only hull compression. If the shape is not perfect, the hull deflects more in some places and buckling instability is the usual failure mode. Inevitable minor deviations are resisted by stiffener rings, but even a one-inch (25 mm) deviation from roundness results in over 30 percent decrease of maximal hydrostatic load and consequently dive depth. The hull must therefore be constructed with high precision. All hull parts must be welded without defects, and all joints are checked multiple times with different methods, contributing to the high cost of modern submarines.
Nycomed, a Swiss drug company which manufactures Actovegin, claims it can be used for circulation and nutrition disturbances, skin grafting, burns, and wound-healing impairment. Actovegin has also been used as a performance enhancer. It has been investigated for use in treatment of polyneuropathy in diabetes, and for stroke. One study found that when tissues suffer from hypoxia caused circulation abnormalities, Actovegin helps capillaries improve circulation by enhancing the neogenic mechanism in blood vessels. Anaphylactic shock has been observed in at least one patient treated with actovegin. There are reports suggesting that Actovegin have ergogenic ability, however one small trial found no apparent benefit from short-term use. Two studies certified Actovegin to have an anti-inflammatory effect. One of the two studies certified Actovegin to reduce Progressive muscular atrophy-induced inflammation in human cells. Another study certified Actovegin to have a positive impact on the growth of muscle cells.
Sources: en.wikipedia.org
oil/fat {\displaystyle {{\textrm {W}}_{\textrm {oil/fat}}}} is the weight of sample, in g. For example, standard methods for determination of SV of vegetable and animal fats are as follows: The SV can also be calculated from the fatty acid composition as determined by gas chromatography (AOCS Cd 3a-94). Handmade soap makers who aim for bar soap use sodium hydroxide (NaOH), commonly known as lye, rather than KOH (caustic potash) which produces soft paste, gel or liquid soaps. In order to calculate the lye amount needed to make bar soap, KOH values of SV can be converted to NaOH values by dividing KOH values by the ratio of the molecular weights of KOH and NaOH (1.403). The theoretical SV of a pure triglyceride molecule can be calculated by the following equation (where MW is its molecular weight):
According to news reports, the execution of Ronald Bert Smith in the state of Alabama on 8 December 2016 allegedly went awry due to the fact he displayed movement soon after midazolam was injected, although prison staff confirmed twice that he was still unconscious before injecting the two fatal drugs. This controversy again stirred concern among the public regarding the effectiveness of the drug in question. In October 2016, the state of Ohio announced that it would resume executions in January 2017, using a formulation of midazolam, vecuronium bromide, and potassium chloride, but this was blocked by a federal judge. On 26 July 2017, Ronald Phillips was executed with a three-drug cocktail including midazolam after the Supreme Court refused to grant a stay. Prior to this, the last execution in Ohio had been that of Dennis McGuire. Murderer Gary Otte's lawyers unsuccessfully challenged his Ohio execution, arguing that midazolam might not protect him from serious pain when the other drugs are administered. He was pronounced dead without incident in about 14 minutes on 13 September 2017. In April 2017, the state of Arkansas carried out a double-execution, of Jack Harold Jones, 52, and Marcel Williams, 46. Arkansas attempted to execute eight people before its supply of midazolam expired on 30 April 2017. Two of them were granted a stay of execution, and another, Ledell Lee, 51, was executed on 20 April 2017. In October 2021, the state of Oklahoma executed inmate John Marion Grant, 60, using midazolam as part of its three-drug cocktail hours after the U.S.
This is a list of investigational sleep apnea drugs, or drugs that are currently under development for clinical use in the treatment of sleep apnea but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action [Reference]". This list was last comprehensively updated in September 2025. It is likely to become outdated with time.
In 1947, the United Gold Coast Convention led by "The Big Six" called for "self-government within the shortest possible time." Following the 1946 Gold Coast legislative election, Kwame Nkrumah, a Ghanaian nationalist who led Ghana from 1957 to 1966 as the country's first prime minister and president, formed the Convention People's Party in 1949 with the motto "self-government now". The party initiated a "positive action" campaign involving non-violent protests, strikes and non-cooperation with the British authorities. Nkrumah was arrested and sentenced to one year imprisonment during this time. In the Gold Coast's 1951 general election, he was elected to Parliament and was released from prison. At midnight on 6 March 1957, the Gold Coast, Ashanti, the Northern Territories, and British Togoland were unified as one single independent dominion within the British Commonwealth under the name Ghana. This was done under the Ghana Independence Act 1957. The flag of Ghana, consisting of the colours red, gold, green, and a black star, dates back to this unification. On 1 July 1960, following the Ghanaian constitutional referendum and Ghanaian presidential election, Nkrumah declared Ghana a republic and assumed the presidency. The nation's Independence Day is 6 March, and 1 July is celebrated as Republic Day. Nkrumah led an authoritarian regime in Ghana, repressing political opposition and conducting elections that were not free and fair. In 1964, a constitutional amendment made Ghana a one-party state, with Nkrumah as president for life of the nation and its party.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.